phase ii cf studi paus price target
eloxx end cash million ensur patient safeti due
pandem eloxx temporarili suspend phase ii studi mutant
patient top-lin data readout expect push enrol
resum feasibl beyond cf eloxx intend file ind autosom
domin polycyst kidney diseas adpkd eloxx also advanc pipelin
preclin retin candid remain overweight howev reduc price
target
phase ii cystic fibrosi studi paus phase ii studi enrol
patient europ mutat
preval nonsens mutat affect cf patient patient receiv
daili subcu inject establish go-forward dose base
chang sweat chlorid safeti primari endpoint measur
sinc cf patient high risk infect phase ii studi
temporarili suspend top-lin data readout previous expect
push enrol continu feasibl
adpkd plan next eloxx intend file ind adpkd
preclinc studi shown dose-depend read-through across common
build preclin data retin diseas eloxx continu advanc intravitr
read-through compound retin diseas singl intravitr inject read-through
compound restor function gene involv melanin product found
retina earlier week arvo virtual meet eloxx present preclin
data mous model nonsens mutat gene show
increas read-though result signific increas melanin eloxx work
extend releas formul monthli quarterli dose eloxx initi focus
usher syndrom type repres case restor mutat
may fail clinic fail gain regulatori approv eloxx may unabl file
ind compani like requir futur fund
eloxx develop drug treat genet diseas caus nonsens mutat
debt total capit
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
remain overweight rate howev cut price target
decreas valu cystic fibrosi roll forward discount period
lower price target base decreas project enterpris valu million
million
valu cf million appli standard multipl
sale million discount back slightli higher prior
valu cf million appli standard multipl
sale million discount back valu cf
europ million appli multipl sale million discount back
slightli higher prior valu cf europ million
appli multipl sale million discount back
increas discount rate base push phase ii cf data
form due could adjust futur base data
continu add million eloxx preclin usher syndrom program
eloxx end cash million owe debt million svb westriv
subtract project debt million versu previous ad project
net cash million divid project market cap million
million share arriv lower price target pleas see exhibit
piper sandler compani estim
page
thousand except per share
research develop
gener administr
incom expens
net loss attribut common stockhold
compani report piper sandler estim
current disclosur inform compani found
